Apontis Pharma AG Total Assets
Apontis Pharma AG total assets. Based on the latest financial reports, Apontis Pharma AG (APPH) holds total assets worth €43.99 Million EUR (≈ $51.43 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Apontis Pharma AG market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Apontis Pharma AG (2018–2024)
Total assets of Apontis Pharma AG from 2018 to 2024. This chart illustrates how Apontis Pharma AG's total assets have evolved over time, based on quarterly financial data. See APPH share price today for real-time trading data and today's change.
Apontis Pharma AG - Asset Composition Analysis
Apontis Pharma AG Total Assets Breakdown (December 2024)
Apontis Pharma AG total assets breakdown as of December 2024. Apontis Pharma AG's total assets of €43.99 Million consist of 52.8% current assets and 47.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.8% |
| Accounts Receivable | €108.07K | 0.2% |
| Inventory | €5.47 Million | 12.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €17.65 Million | 39.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Apontis Pharma AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Apontis Pharma AG short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apontis Pharma AG's current assets represent 52.8% of total assets in 2024, a decrease from 54.7% in 2018.
- Cash Position: Cash and equivalents constituted 34.8% of total assets in 2024, up from 25.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, a decrease from 43.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 39.8% of total assets.
Apontis Pharma AG Competitors by Total Assets
Key competitors of Apontis Pharma AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Apontis Pharma AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.82 | 4.25 | 0.74 |
| Quick Ratio | 4.30 | 3.14 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €17.93 Million | €20.61 Million | €-4.84 Million |
Apontis Pharma AG - Advanced Valuation Insights
This section examines the relationship between Apontis Pharma AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.90 |
| Latest Market Cap to Assets Ratio | 2.06 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | €44.37 Million |
| Market Capitalization | $91.63 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Apontis Pharma AG's assets at a significant premium (2.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Apontis Pharma AG's assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apontis Pharma AG (2018–2024)
The table below shows the annual total assets of Apontis Pharma AG from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €44.37 Million ≈ $51.88 Million |
-22.77% |
| 2023-12-31 | €57.46 Million ≈ $67.18 Million |
-4.00% |
| 2022-12-31 | €59.85 Million ≈ $69.97 Million |
+10.57% |
| 2021-12-31 | €54.13 Million ≈ $63.29 Million |
+82.32% |
| 2020-12-31 | €29.69 Million ≈ $34.71 Million |
-2.93% |
| 2019-12-31 | €30.59 Million ≈ $35.76 Million |
-12.22% |
| 2018-12-31 | €34.84 Million ≈ $40.73 Million |
-- |
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more